Usana Health Sciences Inc Stock Price, News & Analysis

USANA Health Sciences, Inc. (NYSE: USNA) has announced a leadership transition, effective July 1, 2023. Kevin Guest, CEO since 2015, will become Executive Chairman, while Jim Brown, previously President, will take over as CEO. Guest expressed gratitude for his team and confidence in Brown's leadership qualities. Brown emphasized his commitment to advancing USANA’s mission and expanding its market presence. The Board recognizes Guest’s contributions and believes this transition positions USANA for continued growth and success in the health and wellness sector.

USANA Health Sciences, Inc. (USNA) reported its financial results for the fourth quarter and fiscal year 2022, showing a fourth-quarter net sales decline to $228 million from $267 million year-over-year. Q4 diluted EPS fell to $0.66 from $1.03. Full year net sales were $999 million, down 16% from $1,186 million in 2021, with diluted EPS declining 37% to $3.59. The company reiterated its FY 2023 outlook, projecting net sales between $850 million to $950 million and diluted EPS of $2.35 to $3.30.

The active customer base was 490,000, a 13% decrease from the previous year.

USANA Health Sciences (NYSE: USNA) has introduced an Affiliate Program, aimed at expanding its customer and entrepreneur base. The program is currently available in the US, Canada, and Mexico, allowing affiliates to earn 15%–20% commissions on product sales through personal links. CEO Kevin Guest stated that this initiative would help USANA adapt to evolving customer expectations and drive growth. Executive VP Jeannie Price highlighted the program's potential to attract a new market segment, offering customers a chance to earn while sharing their favorite USANA products.

USANA Health Sciences (NYSE: USNA) reported preliminary fiscal year 2022 results, anticipating net sales of approximately $995 million and diluted EPS of about $3.65, surpassing previous guidance. The increase is attributed to strong demand in mainland China following COVID policy shifts. For fiscal year 2023, initial guidance estimates net sales between $850 million and $950 million, with diluted EPS of $2.35 to $3.30. The outlook highlights challenges in growing customer counts from a lower base and ongoing uncertainties in key markets.

Kevin Guest, chairman and CEO of USANA Health Sciences (NYSE: USNA), launches a motivational campaign for January's National Rising Star Month, encouraging individuals to embrace new habits and take risks. Drawing from his bestselling book, All the Right Reasons: 12 Timeless Principles for Living a Life in Harmony, Guest emphasizes the importance of stepping out of comfort zones to discover inner strength. He identifies five key rewards of starting new habits, including increased self-confidence and improved ability to handle stress. Proceeds from his book support feeding hungry children.

USANA Kids Eat delivered over 4,100 bags of food, equating to 164,000 meals, to 40 schools in Utah during the holiday season. This initiative aims to support families facing food insecurity as schools go on break. Michelle Benedict, director of USANA Kids Eat, highlighted the importance of such programs, noting that one in seven children in Utah are at risk of hunger. Volunteers, including USANA executives, actively participated in packing and delivering meals, reflecting USANA's commitment to combating food insecurity.

USANA Health Sciences, Inc. (NYSE:USNA) announced that CFO Doug Hekking will present at the ICR Conference in Orlando, FL, on January 10, 2023, at 3:30 PM ET. Hekking will also engage in one-on-one investor meetings. Investors can access a live audio webcast of the presentation on USANA’s website, with a replay available on the same day. USANA specializes in developing and manufacturing high-quality nutritional supplements and personal care products, serving markets in the US and internationally.